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• Health utility values represent the strength of an individual's preference for specific health-related outcomes • The cost effectiveness of emerging therapies is frequently assessed using cost-utility analyses; these analyses combine utility values with a survival measure to derive quality-adjusted life-years (QALYs) • Health utilities can be obtained directly from generic preference-based utility instruments or indirectly from condition-specific health-related quality-of-life (HRQoL) instruments − Although generic instruments, such as the European Quality of Life-5 Dimensions (EQ-5D), Short Form-6 Dimensions (SF-6D), and Health Utilities Index (HUI), generate utilities that allow comparisons across diseases and can be integrated into cost-utility analyses, they sometimes lack sensitivity to particular aspects of certain conditions − To capture small but important changes in HRQoL specific to certain diseases, condition-specific HRQoL instruments may be used; such instruments are often included in clinical trials • Health authorities, such as the National Institute for Health and Care Excellence (NICE), prefer the EQ5D; however, they acknowledge the need for alternative methods to estimate health utilities when EQ-5D data are unavailable or deemed inappropriate because of failure to capture the specific symptom burden of the disease 1 − In such situations, utility mapping algorithms can be used to estimate health utilities from condition-specific HRQoL instruments • Mapping algorithms have been developed for various cancers to derive EQ-5D utilities from the cancerspecific European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) − Algorithms are available for multiple myeloma, breast cancer, lung cancer, gastric cancer, and esophageal cancer, as well as an algorithm combining patients with various cancer types • Published utility values are not available for patients with polycythemia vera (PV), a myeloproliferative neoplasm (MPN) characterized by red blood cell overproduction • In the RESPONSE trial, a Phase III registration trial for ruxolitinib in PV, symptom burden control was an important treatment goal as current therapies often inadequately control disease-related symptoms 2 − HRQoL data were collected using multiple instruments in RESPONSE, including the EORTC QLQ-C30 and the myeloproliferative neoplasm symptom assessment form (MPN-SAF) 2 , a condition-specific instrument that focuses on the most impactful symptoms of PV 3
• A literature search was conducted to identify algorithms that mapped EORTC QLQ-C30 data onto the EQ-5D and provided sufficient information to conduct independent analyses • Table 1 summarizes the identified mapping algorithms that were explored in this study • Each algorithm was used to estimate utility values for PV based on baseline patient-reported EORTC QLQ-C30 responses from the total intention-to-treat population in the RESPONSE trial − For publications providing more than one regression model, all possible models were explored
• The objective of this study was to estimate utility values for PV using existing mapping algorithms • External validity in other cancers not good 6 Jang et al., 2010 (Canada) 7 Non-small cell lung cancer (n = 172)
• Linear regression • Used US EQ-5D tariffs • Backward variable elimination using Akaike Information Criterion to reduce full model to include only variables that best predict utility • Performed well when tested external validity with breast cancer (PRIME study) Proskorovsky et al., 2014 (UK, Germany) 12 Multiple myeloma (n = 154)
• Multiple linear regression • Mapped combined EORTC QLQ-C30 + QLQ MY20 and EORTC QLQ-C30 alone; EORTC QLQ-C30 alone was sufficient for predicting utility • Generated trimmed models by removing non-significant items; trimmed model had optimal generalizability • Predicted well when tested external validity with NonHodgkin lymphoma (n = 108)
Table 1. Published Algorithms for Mapping the EORTC QLQ-C30 onto the EQ-5D
* Algorithm first published by Crott and Briggs 2010 4 ; however, further evaluated in the Crott, 2013 and Crott, 2014 publications 5; 6 . Two more recent publications presented the same preference weights, which included additional decimal places versus the initial publication and corrected a suspected error in the coefficient for insomnia from the original publication; the more recent version was used for calculations. Abbreviations: ERUM = episodic random utility model; MAE = mean absolute error; MLE RE= maximum likelihood estimation random effects; MSE = mean square error; OLS = ordinary least squares; RMSE = root mean square error; TTO = time trade off.
• In addition to mapping utility values using the published algorithms for mapping EORTC QLQ-C30 onto the EQ-5D, the MF-8D mapping algorithm was also evaluated • The MF-8D is a condition-specific preference-based measure that was developed for myelofibrosis (MF), another MPN 15 − It combines 5 dimensions from the myelofibrosis symptom assessment form (MF-SAF) with 3 dimensions from the EORTC QLQ-C30 • Clinicians were consulted regarding the appropriateness of the MF-8D for patients with PV and the feasibility of substituting responses from the MPN-SAF for those from the MF-SAF • The MF-8D was adapted for PV using two minor assumptions ( Table 2) − Abdominal pain in the MPN-SAF was substituted for pain under ribs on left side from the MF-SAF − Bone pain from the MPN-SAF was substituted for bone or muscle pain from the MF-SAF
• Two versions of the MF-8D (RE MLE consistent model) were assessed, one using Rasch weighting for response levels of MPN-SAF items and the other using equal weighting between response levels • All algorithms were compared in terms of their ability to assess the most prominent symptoms experienced by patients with PV − Assessment was based on whether or not the algorithms could account for the primary symptoms of PV (i.e., those reported by ≥50% of patients in a study by Emanuel and colleagues 3 ) • Utility values calculated from the various mapping algorithms were compared Pain (Model 3 and 4)  
• Clinical experts suggested that the MF-8D algorithm would better capture HRQoL in PV than published algorithms developed for various cancers, as key symptoms driving HRQoL, such as pruritus and night sweats, are only captured using the MF-8D • A comparison of the ability of each algorithm to assess the key symptoms of PV is provided in Table 3 − The MF-8D captured the 6 of the 8 most prominent symptoms experienced by patients with PV; other algorithms were able to assess up to 5 symptoms − The MF-8D was the only algorithm that directly captured the effects of pruritus, night sweats, and abdominal discomfort on utility; however, it may not adequately assess early satiety and concentration problems • Figure 1 summarizes the utility values calculated for PV using each algorithm − Utility values ranged from 0.6973 to 0.9154; this wide range is likely due to differences in the EORTC QLQ-C30 dimensions included in each algorithm and corresponding preference weights − Utility values derived using the MF-8D were in the range of those calculated from the published algorithms; a utility of 0.7276 was calculated using the Rasch weighting version, while a utility of 0.7859 was calculated with the equal weighting version chronic conditions in the US; although PV was not included, the ICD-9 code 289 for other blood disorders likely provides a meaningful approximation for PV, reporting a mean EQ-5D of 0.749 16 − Assuming this utility value is a good approximation for PV, the utility values calculated with the MF-8D (Rasch), Jang (Full), Proskorovsky (Trimmed), and Versteegh (Models 3 and 4) algorithms provide the most reasonable estimates (i.e., fall within +/-0.025) • Variability across algorithms suggests that clinical input is important for assessing which algorithm is most relevant for the disease area in question − Clinical input should guide algorithm selection in the base case of a cost-effectiveness analysis − To address underlying uncertainty surrounding mapped utility values, several alternative algorithms should be explored in sensitivity analyses • The MF-8D algorithm is expected to better predict treatment-specific differences in HRQoL of patients with PV than the algorithms developed for other cancers as it captures important symptoms such as pruritus, night sweats, and abdominal discomfort − Thus, this condition-specific, preference-based measure may be more appropriate than mapping algorithms from other cancers when deriving utilities for the economic evaluations of emerging therapies in PV 
